Characteristic | Mean | SD |
---|---|---|
Time since first symptoms (years) | 11.5 | 9.5 |
Time since diagnosis (years) | 9.5 | 8.3 |
Characteristic | n | % |
Disease course: a | Â | Â |
 Relapsing-remitting | 2136 | 72.2 |
 Secondary progressive | 351 | 11.9 |
 Primary progressive | 437 | 14.8 |
 Progressive-relapsing | 26 | 0.9 |
 Clinically Isolated Syndrome | 8 | 0.3 |
Number of patient-reported relapses (not physician confirmed) in past year: | Â | Â |
0 | 1455 | 49.1 |
1 | 652 | 22.0 |
2 | 314 | 10.6 |
3 | 130 | 4.4 |
4 | 52 | 1.8 |
>4 | 110 | 3.7 |
Uncertain | 253 | 8.5 |
Current patient-reported symptoms: b | Â | Â |
 Fatigue | 2215 | 74.7 |
 Impaired coordination or balance | 1834 | 61.8 |
 Numbness and tingling | 1814 | 61.2 |
 Problems with thinking or memory | 1599 | 53.9 |
 Decreased strength in arms or legs | 1548 | 52.2 |
 Difficulty walking or moving legs | 1442 | 48.6 |
 Bladder problems | 1350 | 45.5 |
 Spasticity | 1262 | 42.5 |
 Pain | 895 | 30.2 |
 Visual symptoms | 889 | 30.0 |
 Bowel problems | 774 | 26.1 |
 Sexual dysfunction | 734 | 24.7 |
 Difficulty with speech or swallowing | 637 | 21.5 |
 Difficulty moving arms or hands | 621 | 20.9 |
 Tremor | 527 | 17.8 |
 Otherc | 239 | 8.1 |
Disease-modifying therapy: | Â | Â |
GA | 1475 | 49.7 |
IFNβ-1a IM | 604 | 20.4 |
IFNβ-1a SC | 470 | 15.8 |
IFNβ-1b | 417 | 14.1 |